Findings

What do systematic reviews say?

28 questions · 28 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 32.1%GRADE not reported 0 · 0%Very low 7 · 25%Low 3 · 10.7%Moderate 1 · 3.6%High 8 · 28.6%

Leflunomide vs methotrexate

Death · adults with renal vasculitis for maintenance therapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs methotrexate

Kidney function · adults with renal vasculitis for maintenance therapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs methotrexate

Dialysis · adults with renal vasculitis for maintenance therapy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs methotrexate

Relapse · adults with renal vasculitis for maintenance therapy

Leflunomide showed no clear difference in relapse compared with methotrexate (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 0.5 [0.22, 1.11]
1 study · 54 participants
Low

Leflunomide vs methotrexate

Serious adverse events* · adults with renal vasculitis for maintenance therapy

Leflunomide showed no clear difference in serious adverse events* compared with methotrexate (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 11.81 [0.69, 203.68]
1 study · 54 participants
Low

Leflunomide vs methotrexate

Infection · adults with renal vasculitis for maintenance therapy

Leflunomide showed no clear difference in infection compared with methotrexate (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [0.27, 106.88]
1 study · 54 participants
Low

Leflunomide vs no leflunomide regimen

End‐stage renal disease · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether leflunomide regimen changes end‐stage kidney disease compared with no leflunomide regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 0.68 [0.17, 2.65]
1 study · 85 participants
Very low

Leflunomide vs no leflunomide regimen

Complete remission · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether leflunomide regimen changes complete remission compared with no leflunomide regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 1.08 [0.8, 1.46]
4 studies · 282 participants
Very low

Leflunomide vs no leflunomide regimen

GFR loss ≥ 50% · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs no leflunomide regimen

Annual GFR loss (mL/min/1.73 m2) · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs no leflunomide regimen

Death (any cause) · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs no leflunomide regimen

Infection · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether leflunomide regimen changes infection compared with no leflunomide regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 0.97 [0.45, 2.09]
3 studies · 387 participants
Very low

Leflunomide vs no leflunomide regimen

Malignancy · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs placebo, 6 months

For outcome · patients with rheumatoid arthritis in adults

The review found no eligible studies for this question.

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs placebo, 6 months

ACR 50 response at 6 months · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 2.32 [1.32, 4.05]
1 study · 221 participants
High

Leflunomide vs placebo, 6 months

HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 679 participants
High

Leflunomide vs placebo, 6 months

Pain change (0‐100 mm VAS) · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 724 participants
High

Leflunomide vs placebo, 6 months

Radiographic joint changes · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide showed no clear difference in radiographic change (Change in Sharp score) compared with placebo, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 1.23 [0.91, 1.66]
1 study · 380 participants
High

Leflunomide vs placebo, 6 months

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 727 participants
High

Summary of findings: leflunomide + methotrexate vs methotrexate

Change in pain (0‐100 mm VAS) · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
High